Latest Breaking News On - Clene inc - Page 4 : comparemela.com

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8® for the treatment of ALS with the objective of submitting an NDA in 2024Released long-term data from the open-label extension

North American Morning Briefing : Stock Futures -2- - 2024-03-11

Bluegreen Vacations Holding Corp is expected to report for 4Q. Calavo Growers is expected to report $0.15 for 1Q. Casey s General Stores is expected to report $2.10 for 3Q. Clene Inc. -March 11, 2024 at 06:19 am EDT - MarketScreener

North American Morning Briefing: Stock Futures -2-

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Long-term CNM-Au8 treatment demonstrated significant and clinically meaningful improvement of vision as measured by low contrast letter acuity (LC.

Clene (CLNN) Reports Significant Survival Benefit With CNM-Au8 Treatment in ALS EAP Compassionate Use Programs